CareDx

Academia Sinica in Taiwan leads interdisciplinary research in biotech, pharmaceuticals, and medical science through advanced facilities like RNA Technology Platform, Taiwan Mouse Clinic, BioTReC Nucleic Acid Pilot Plant, and Taiwan Biobank, fostering global healthcare advancements.

CareDx to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The company is a leading precision medicine provider for transplant patients.

TC BioPharm partners with CareDx for pharmacokinetic analysis in ACHIEVE trial, evaluating TCB008, an allogeneic gamma delta T cell therapy for AML/MDS, using CareDx's AlloCell solution.

CareDx partners with TC BioPharm to use AlloCell for pharmacokinetic analysis in the ACHIEVE trial, evaluating TCB008 for AML/MDS patients, expanding into hematology oncology.

CareDx to participate in Jefferies London Healthcare Conference, Stephens Investment Conference, and Piper Sandler Healthcare Conference. Webcast available on investors.caredx.com.

CareDx reports Q3 2024 revenue of $82-83M, up 23% YoY, with Testing Services volume at 44,600, up 16% YoY. Testing services revenue is $60-61M, up 26% YoY, and Patient and Digital Solutions revenue is $11.9M, up 20% YoY. The company ended Q3 with $240M in cash, cash equivalents, and marketable securities and no debt. Earnings to be reported on November 4, 2024.